Reviewing the ketamine model for schizophrenia

Journal of Psychopharmacology

Volumn 28, Issue 4, 2014, Pages 287-302

  Frohlich, Joel ^a   Van Horn, John D ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

glutamate; Ketamine; N methyl D aspartate receptor; schizophrenia

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; GLUTAMIC ACID; KAPPA OPIATE RECEPTOR; KETAMINE; N ALLYLNORMETAZOCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SIGMA OPIATE RECEPTOR; 4 AMINOBUTYRIC ACID; PHENCYCLIDINE;

BRAIN FUNCTION; COGNITION; CONNECTOME; DEFAULT MODE NETWORK; DISEASE MODEL; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; GABAERGIC SYSTEM; GLUTAMATERGIC TRANSMISSION; HUMAN; INTERNEURON; NERVE CELL STIMULATION; NEUROTRANSMISSION; NONHUMAN; ONSET AGE; OSCILLATORY POTENTIAL; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; REVIEW; SCHIZOPHRENIA; SYNAPTIC INHIBITION; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PSYCHOLOGY;

AGE OF ONSET; ANIMALS; DOPAMINE; GAMMA-AMINOBUTYRIC ACID; HUMANS; KETAMINE; PHENCYCLIDINE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84896743886     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113512909     Document Type: Review

References (214)

1. Aalto S, Ihalainen J, Hirvonen J, et al. Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology. 2005 ; 182: 375-383
2. Abi-Dargham A, Mawlawi O, Lombardo I, et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci. 2002 ; 22: 3708-3719
3. Diagnostic and Statistical Manual of Mental Disorders. 2000 ) Diagnostic and Statistical Manual of Mental Disorders. Fourth edition, text revision. Washington, DC: American Psychiatric Association. Washington, DC: American Psychiatric Association ; 2000 :
4. Amitai N, Kuczenski R, Behrens MM, et al. Repeated phencyclidine administration alters glutamate release and decreases GABA markers in the prefrontal cortex of rats. Neuropharmacology. 2012 ; 62: 1422-1431
5. An der Heiden U. Schizophrenia as a dynamical disease. Pharmacopsychiatry. 2006 ; 39: S36 - S42
6. Andreone N, Tansella M, Cerini R, et al. Cerebral atrophy and white matter disruption in chronic schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2007 ; 257: 3-11
7. Anticevic A, Gancsos M, Murray JD, et al. NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia. Proc Natl Acad Sci U S A. 2012 ; 109: 16720-16725
8. Anver H, Ward PD, Magony A, et al. NMDA receptor hypofunction phase couples independent γ-oscillations in the rat visual cortex. Neuropsychopharmacology. 2011 ; 36: 519-528
9. Aroni F, Iacovidou N, Dontas I, et al. Pharmacological aspects and potential new clinical applications of ketamine: Reevaluation of an old drug. J Clin Pharmacol. 2009 ; 49: 957-964
10. Baldeweg T, Spence S, Hirsch SR, et al. Gamma-band electroencephalographic oscillations in a patient with somatic hallucinations. Lancet. 1998 ; 352: 620-621
11. Barr MS, Farzan F, Arenovich T, et al. The effect of repetitive transcranial magnetic stimulation on gamma oscillatory activity in schizophrenia. PloS One. 2011 ; 6: e22627
12. Barr MS, Farzan F, Tran LC, et al. Evidence for excessive frontal evoked gamma oscillatory activity in schizophrenia during working memory. Schizophr Res. 2010 ; 121: 146-152
13. Bassett DS, Bullmore E, Verchinski BA, et al. Hierarchical organization of human cortical networks in health and schizophrenia. J Neurosci. 2008 ; 28: 9239-9248
14. Baum VC, Tecson ME. Ketamine inhibits transsarcolemmal calcium entry in guinea pig myocardium: Direct evidence by single cell voltage clamp. Anesth Analg. 1991 ; 73: 804-807
15. Behrens MM, Ali SS, Dao DN, et al. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science. 2007 ; 318: 1645-1647
16. Benoit E, Carratu MR, Dubois JM, et al. Mechanism of action of ketamine in the current and voltage clamped myelinated nerve fibre of the frog. Br J Pharmacol. 1986 ; 87: 291-297
17. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000 ; 47: 351-354
18. Bleuler E. Die prognose der dementia praecox. Allg Z Psychiatr. 1908 ; 65: 436-464
19. Bossong MG, Niesink RJM. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Prog Neurobiol. 2010 ; 92: 370-385
20. Breakspear M. The nonlinear theory of schizophrenia. Aust N Z J Psychiatry. 2006 ; 40: 20-35
21. Breier A, Su TP, Saunders R, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A. 1997 ; 94: 2569-2574
22. Bucci P, Mucci A, Merlotti E, et al. Induced gamma activity and event-related coherence in schizophrenia. Clin EEG Neurosci. 2007 ; 38: 96-104
23. Calhoun VD, Eichele T, Pearlson G. Functional brain networks in schizophrenia: A review. Front Hum Neurosci. 2009 ; 3: 17
24. Carlino E, Sigaudo M, Pollo A, et al. Nonlinear analysis of electroencephalogram at rest and during cognitive tasks in patients with schizophrenia. J Psychiatry Neurosci. 2012 ; 37: 259-266
25. Castner SA, Arriza JL, Roberts JC, et al. Reversal of ketamine-induced working memory impairments by the GABAAalpha2/3 agonist TPA023. Biol Psychiatry. 2010 ; 67: 998-1001
26. Chatterton JE, Awobuluyi M, Premkumar LS, et al. Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits. Nature. 2002 ; 415: 793-798
27. Cho RY, Konecky RO, Carter CS. Impairments in frontal cortical gamma synchrony and cognitive control in schizophrenia. Proc Natl Acad Sci U S A. 2006 ; 103: 19878-19883
28. Chumakov I, Blumenfeld M, Guerassimenko O, et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A. 2002 ; 99: 13675-13680
29. Cochran SM, Kennedy M, McKerchar CE, et al. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: Differential modulation by antipsychotic drugs. Neuropsychopharmacology. 2003 ; 28: 265-275
30. Coffey DS. Self-organization, complexity and chaos: The new biology for medicine. Nat Med. 1998 ; 4: 882-885
31. Coppa-Hopman R, Galle J, Pimkine D. D1 receptor antagonist-induced long-term depression in the medial prefrontal cortex of rat, in vivo: An animal model of psychiatric hypofrontality. J Psychopharmacol. 2009 ; 23: 672-685
32. Corssen G, Domino EF. Dissociative anesthesia: Further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesth Analg. 1966 ; 45: 29-40
33. Coyle JT, Basu A, Benneyworth M, et al. Glutamatergic synaptic dysregulation in schizophrenia: Therapeutic implications. Hand Exp Pharmacol. 2012 ; 213: 267-295
34. Smoller JW, Craddock N, et al. Identification of risk loci with shared effects on five major psychiatric disorders: A genome-wide analysis. Lancet. 2013 ; 381: 1371-1379
35. Cunningham MO, Hunt J, Middleton S, et al. Region-specific reduction in entorhinal gamma oscillations and parvalbumin-immunoreactive neurons in animal models of psychiatric illness. J Neurosci. 2006 ; 26: 2767-2776
36. D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology. 2004 ; 29: 1558-1572
37. Daniell LC. The noncompetitive N-methyl-D-aspartate antagonists, MK-801, phencyclidine and ketamine, increase the potency of general anesthetics. Pharmacol Biochem Behav. 1990 ; 36: 111-115
38. Dawson N, Morris BJ, Pratt JA. Subanaesthetic ketamine treatment alters prefrontal cortex connectivity with thalamus and ascending subcortical systems. Schizophr Bull. 2013 ; 39: 366-377
39. Dawson N, Xiao X, McDonald M, et al. Sustained NMDA receptor hypofunction induces compromised neural systems integration and schizophrenia-like alterations in functional brain networks. Cereb Cortex. 2012 ;:
40. Deakin JFW, Lees J, McKie S, et al. Glutamate and the neural basis of the subjective effects of ketamine: A pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry. 2008 ; 65: 154-164
41. Debonnel G. Current hypotheses on sigma receptors and their physiological role: Possible implications in psychiatry. J Psychiatry Neurosci. 1993 ; 18: 157-172
42. Dickinson R, Awaiz S, Whittington MA, et al. The effects of general anaesthetics on carbachol-evoked gamma oscillations in the rat hippocampus in vitro. Neuropharmacology. 2003 ; 44: 864-872
43. Dima D, Dillo W, Bonnemann C, et al. Reduced P300 and P600 amplitude in the hollow-mask illusion in patients with schizophrenia. Psychiatry Res. 2011 ; 191: 145-151
44. Domino EF, Chodoff P, Corssen G. Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther. 1965 ; 6: 279-291
45. Driesen NR, McCarthy G, Bhagwagar Z, et al. Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. Mol Psychiatry. 2013 2013 ; 18: 1199-1204
46. Edelman GM, Tononi G A Universe of Consciousness: How Matter Becomes Imagination. New York: Basic Books ; 2000 :
47. Ehrlichman RS, Gandal MJ, Maxwell CR, et al. N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia. Neuroscience. 2009 ; 158: 705-712
48. European Monitoring Centre for Drugs and Drug Addiction (2008) Legal reports. Substances and classifications table. Available at: http://www.emcdda.europa.eu/html.cfm/index5175EN.html. (accessed 10 October 2013)
49. Fain G Molecular and Cellular Physiology of Neurons. 1999 ) Molecular and Cellular Physiology of Neurons. Eastern Economy Edition. New Delhi: Prentice-Hall of India. New Delhi: Prentice-Hall of India ; 1999 :
50. Farber NB, Olney JW. Drugs of abuse that cause developing neurons to commit suicide. Brain Res Dev Brain Res. 2003 ; 147: 37-45
51. Farzan F, Barr MS, Sun Y, et al. Transcranial magnetic stimulation on the modulation of gamma oscillations in schizophrenia. Ann N Y Acad Sci. 2012 ; 1265: 25-35
52. Feinberg I. Schizophrenia: Caused by a fault in programmed synaptic elimination during adolescence?. J Psychiatr Res. 1982 ; 17: 319-334
53. Ferrarelli F, Massimini M, Peterson MJ, et al. Reduced evoked gamma oscillations in the frontal cortex in schizophrenia patients: A TMS/EEG study. Am J Psychiatry. 2008 ; 165: 996-1005
54. Ferrarelli F, Tononi G. The thalamic reticular nucleus and schizophrenia. Schizophr Bull. 2011 ; 37: 306-315
55. Ferrari MCL, Kimura L, Nita LM, et al. Structural brain abnormalities in early-onset schizophrenia. Arq Neuropsiquiatr. 2006 ; 64: 741-746
56. Fraiman D, Balenzuela P, Foss J, et al. Ising-like dynamics in large-scale functional brain networks. Phys Rev E Stat Nonlin Soft Matter Phys. 2009 ; 79: 061922
57. Frantseva M, Cui J, Farzan F, et al. Disrupted cortical conductivity in schizophrenia: TMS-EEG study. Cereb Cortex. 2012 ;:
58. Frenkel C, Urban BW. Molecular actions of racemic ketamine on human CNS sodium channels. Br J Anaesth. 1992 ; 69: 292-297
59. Friston KJ. Theoretical neurobiology and schizophrenia. Br Med Bull. 1996 ; 52: 644-655
60. Giovannini MG, Camilli F, Mundula A, et al. Glutamatergic regulation of acetylcholine output in different brain regions: A microdialysis study in the rat. Neurochem Int. 1994 ; 25: 23-26
61. Gloveli T, Dugladze T, Saha S, et al. Differential involvement of oriens/pyramidale interneurones in hippocampal network oscillations in vitro. J Physiol. 2005 ; 562: 131-147
62. Goldman MB, Torres IJ, Keedy S, et al. Reduced anterior hippocampal formation volume in hyponatremic schizophrenic patients. Hippocampus. 2007 ; 17: 554-562
63. Goldman-Rakic PS, Castner SA, Svensson TH, et al. Targeting the dopamine D1 receptor in schizophrenia: Insights for cognitive dysfunction. Psychopharmacology. 2004 ; 174: 3-16
64. Gottesmann C. The dreaming sleep stage: A new neurobiological model of schizophrenia?. Neuroscience. 2006 ; 140: 1105-1115
65. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia. Neuroscience. 1991 ; 41: 1-24
66. Granger B. [Synaptogenesis and synaptic pruning: Role in triggering schizophrenia]. Presse Med. 1996 ; 25: 1595-1598
67. Gupta A, Devi LA, Gomes I. Potentiation of μ-opioid receptor-mediated signaling by ketamine. J Neurochem. 2011 ; 119: 294-302
68. Haenschel C, Bittner RA, Waltz J, et al. Cortical oscillatory activity is critical for working memory as revealed by deficits in early-onset schizophrenia. J Neurosci. 2009 ; 29: 9481-9489
69. Hahn C-G, Wang H-Y, Cho D-S, et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med. 2006 ; 12: 824-828
70. Haimovici A, Tagliazucchi E, Balenzuela P, et al. Brain organization into resting state networks emerges at criticality on a model of the human connectome. Phys Rev Lett. 2013 ; 110: 178101
71. Hájos N, Pálhalmi J, Mann EO, et al. Spike timing of distinct types of GABAergic interneuron during hippocampal gamma oscillations in vitro. J Neurosci. 2004 ; 24: 9127-9137
72. Hamm JP, Gilmore CS, Picchetti NAM, et al. Abnormalities of neuronal oscillations and temporal integration to low- and high-frequency auditory stimulation in schizophrenia. Biol Psychiatry. 2011 ; 69: 989-996
73. Hasegawa M, Kinoshita H, Amano M, et al. MK-801 increases endogenous acetylcholine release in the rat parietal cortex: A study using brain microdialysis. Neurosci Lett. 1993 ; 150: 53-56
74. Hashimoto K. [Role of sigma-1 receptors in neural plasticity and in antipsychotic action]. Nihon shinkei seishin yakurigaku zasshi. 2010 ; 30: 123-127
75. Hashimoto T, Volk DW, Eggan SM, et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci. 2003 ; 23: 6315-6326
76. Hayashi T, Su T-P. Sigma-1 receptor ligands: Potential in the treatment of neuropsychiatric disorders. CNS Drugs. 2004 ; 18: 269-284
77. Hayashi T, Su T-P. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell. 2007 ; 131: 596-610
78. Herrmann CS, Demiralp T. Human EEG gamma oscillations in neuropsychiatric disorders. Clin Neurophysiol. 2005 ; 116: 2719-2733
79. Hirota K. Ketamine: Its mechanism(s) of action and unusual clinical uses. Br J Anaesth. 1996 ; 77: 441-444
80. Hirota K, Hashimoto Y, Lambert DG. Interaction of intravenous anesthetics with recombinant human M1 - M3 muscarinic receptors expressed in Chinese hamster ovary cells. Anesth Analg. 2002 ; 95: 1607-1610
81. Hirota K, Okawa H, Appadu BL, et al. Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells. Anesthesiology. 1999 ; 90: 174-182
82. Ho Y-L, Lin C, Lin Y-H, et al. The prognostic value of non-linear analysis of heart rate variability in patients with congestive heart failure-a pilot study of multiscale entropy. PloS One. 2011 ; 6: e18699
83. Hoffman RE, McGlashan TH. Synaptic elimination, neurodevelopment, and the mechanism of hallucinated 'voices' in schizophrenia. Am J Psychiatry. 1997 ; 154: 1683-1689
84. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci. 2007 ; 27: 11496-11500
85. Hong LE, Summerfelt A, Buchanan RW, et al. Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. Neuropsychopharmacology. 2010 ; 35: 632-640
86. Horváth ZC, Czopf J, Buzsáki G. MK-801-induced neuronal damage in rats. Brain Res. 1997 ; 753: 181-195
87. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: Version III - the final common pathway. Schizophr Bull. 2009 ; 35: 549-562
88. Hustveit O, Maurset A, Oye I. Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol. 1995 ; 77: 355-359
89. Ishikawa M, Hashimoto K. The role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases. J Receptor Ligand Channel Res. 2010 ; 3: 25-36
90. IshimaTFujitaYKohnoM. (2009) Improvement of phencyclidine-induced cognitive deficits in mice by subsequent subchronic administration of fluvoxamine, but not sertraline. The Open Clinical Chemistry Journal2: 7-11. Available at: http://www.benthamscience.com/open/tocchemj/articles/V002/ 7TOCCHEMJ.pdf
91. Javitt DC Integrating the Neurobiology of Schizophrenia. Abi-Dargham A Guillin O, ed. International Review of Neurobiology, San Diego: Academic Press ; 2007: 70-96.
92. Javitt DC, Balla A, Burch S, et al. Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists. Neuropsychopharmacology. 2004 ; 29: 300-307
93. Javitt DC, Zukin SR, Heresco-Levy U, et al. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull. 2012 ; 38: 958-966
94. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003 ; 160: 13-23
95. Kapur S, Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors-implications for models of schizophrenia. Mol Psychiatry. 2002 ; 7: 837-844
96. Karlsgodt KH, Robleto K, Trantham-Davidson H, et al. Reduced dysbindin expression mediates N-methyl-D-aspartate receptor hypofunction and impaired working memory performance. Biol Psychiatry. 2011 ; 69: 28-34
97. Karlsson P, Farde L, Halldin C, et al. PET study of D1 dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry. 2002 ; 159: 761-767
98. Kashima H. Frontal dysfunction of chronic schizophrenia - the pros and cons in neuropsychological assessment. Yakubutsu, seishin, kōdō. 1991 ; 11: 83-88
99. Keane BP, Silverstein SM, Barch DM, et al. The spatial range of contour integration deficits in schizophrenia. Exp Brain Res. 2012 ; 220: 251-259
100. Kehrer C, Maziashvili N, Dugladze T, et al. Altered excitatory-inhibitory balance in the NMDA-hypofunction model of schizophrenia. Front Mol Neurosci. 2008 ; 1: 6
101. Kim S-Y, Lee H, Kim H-J, et al. In vivo and ex vivo evidence for ketamine-induced hyperglutamatergic activity in the cerebral cortex of the rat: Potential relevance to schizophrenia. NMR. Biomed. 2011 ; 24: 1235-1242
102. Kinney JW, Davis CN, Tabarean I, et al. A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J Neurosci. 2006 ; 26: 1604-1615
103. Kocsis B. Differential role of NR2A and NR2B subunits in N-methyl-D-aspartate receptor antagonist-induced aberrant cortical gamma oscillations. Biol Psychiatry. 2012 ; 71: 987-995
104. Kometer M, Schmidt A, Jäncke L, et al. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. J Neurosci. 2013 ; 33: 10544-10551
105. Korotkova T, Fuchs EC, Ponomarenko A, et al. NMDA receptor ablation on parvalbumin-positive interneurons impairs hippocampal synchrony, spatial representations, and working memory. Neuron. 2010 ; 68: 557-569
106. Kunitachi S, Fujita Y, Ishima T, et al. Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: Role of sigma-1 receptors. Brain Res. 2009 ; 1279: 189-196
107. Laruelle M, Abi-Dargham A, Van Dyck CH, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A. 1996 ; 93: 9235-9240
108. Lau C-I, Wang H-C, Hsu J-L, et al. Does the dopamine hypothesis explain schizophrenia?. Rev Neurosci. 2013 ; 24: 389-400
109. Law AJ, Deakin JF. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport. 2001 ; 12: 2971-2974
110. Lee S-H, Wynn JK, Green MF, et al. Quantitative EEG and low resolution electromagnetic tomography (LORETA) imaging of patients with persistent auditory hallucinations. Schizophr Res. 2006 ; 83: 111-119
111. Lee YJ, Zhu YS, Xu YH, et al. Detection of non-linearity in the EEG of schizophrenic patients. Clin Neurophysiol. 2001 ; 112: 1288-1294
112. LenaIMuffatSDeschauxO (2006) Dreaming and schizophrenia have the same neurochemical background. J Sleep Res13: 141. Available at: http:// onlinelibrary.wiley.com/store/10.1111/j.1365-2869.2004.00410.x/asset/j. 1365-2869.2004.00410.x.pdf?v=1&t=hnpgrdwt&s= a6df4f3cfc4169b1b988d7b48eb0c21198b17904
113. Li D, He L. Association study between the NMDA receptor 2B subunit gene (GRIN2B) and schizophrenia: A HuGE review and meta-analysis. Genet Med. 2007a ; 9: 4-8
114. Li D, He L. G72/G30 genes and schizophrenia: a systematic meta-analysis of association studies. Genetics. 2007b ; 175: 917-922
115. Liemburg EJ, Knegtering H, Klein HC, et al. Antipsychotic medication and prefrontal cortex activation: A review of neuroimaging findings. Eur Neuropsychopharmacol. 2012 ; 22: 387-400
116. Löscher W, Annies R, Hönack D. The N-methyl-D-aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats. Neurosci Lett. 1991 ; 128: 191-194
117. Lynall M-E, Bassett DS, Kerwin R, et al. Functional connectivity and brain networks in schizophrenia. J Neurosci. 2010 ; 30: 9477-9487
118. Ma J, Leung LS. The supramammillo-septal-hippocampal pathway mediates sensorimotor gating impairment and hyperlocomotion induced by MK-801 and ketamine in rats. Psychopharmacology. 2007 ; 191: 961-974
119. McGrath J, Saha S, Chant D, et al. Schizophrenia: A concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008 ; 30: 67-76
120. Mackenzie B, Erickson JD. Sodium-coupled neutral amino acid (System N/A) transporters of the SLC38 gene family. Pflugers Arch. 2004 ; 447: 784-795
121. Maeng S, Zarate CA, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5- methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008 ; 63: 349-352
122. Manor B, Lipsitz LA. Physiologic complexity and aging: Implications for physical function and rehabilitation. Prog Neuropsychopharmacol Biol Psychiatry. 2013 ; 45: 287-293
123. Metherate R, Cruikshank SJ. Thalamocortical inputs trigger a propagating envelope of gamma-band activity in auditory cortex in vitro. Exp Brain Res. 1999 ; 126: 160-174
124. Morris BJ, Cochran SM, Pratt JA. PCP: From pharmacology to modelling schizophrenia. Curr Opin Pharmacol. 2005 ; 5: 101-106
125. Mulert C, Kirsch V, Pascual-Marqui R, et al. Long-range synchrony of γ oscillations and auditory hallucination symptoms in schizophrenia. Int J Psychophysiol. 2011 ; 79: 55-63
126. Musso F, Brinkmeyer J, Ecker D, et al. Ketamine effects on brain function-simultaneous fMRI/EEG during a visual oddball task. NeuroImage. 2011 ; 58: 508-525
127. Nagai T, Kitahara Y, Shiraki A, et al. Dysfunction of dopamine release in the prefrontal cortex of dysbindin deficient sandy mice: An in vivo microdialysis study. Neurosci Lett. 2010 ; 470: 134-138
128. Nakanishi T, Kekuda R, Fei YJ, et al. Cloning and functional characterization of a new subtype of the amino acid transport system N. Am J Physiol Cell Physiol. 2001 ; 281: C1757 - C1768
129. Newcomer JW, Farber NB, Jevtovic-Todorovic V, et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology. 1999 ; 20: 106-118
130. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol. 2002 ; 67: 53-83
131. Niesters M, Khalili-Mahani N, Martini C, et al. Effect of subanesthetic ketamine on intrinsic functional brain connectivity: A placebo-controlled functional magnetic resonance imaging study in healthy male volunteers. Anesthesiology. 2012 ; 117: 868-877
132. Norris PR, Stein PK, Morris JA. Reduced heart rate multiscale entropy predicts death in critical illness: A study of physiologic complexity in 285 trauma patients. J Crit Care. 2008 ; 23: 399-405
133. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995 ; 52: 998-1007
134. Olney JW, Farber NB. Discussion of Bogerts' temporolimbic system theory of paranoid schizophrenia. Schizophr Bull. 1997 ; 23: 533-536
135. Olney JW, Newcomer JW, Farber N B. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res. 1999 ; 33: 523-533
136. Otero-Siliceo E, Arriada-Mendicoa N. Is it healthy to be chaotic?. Med Hypotheses. 2003 ; 60: 233-236
137. Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: Evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther. 1992 ; 260: 1209-1213
138. Pettersson-Yeo W, Allen P, Benetti S, et al. Dysconnectivity in schizophrenia: Where are we now?. Neurosci Biobehav Rev. 2011 ; 35: 1110-1124
139. Pfeiffer A, Brantl V, Herz A, et al. Psychotomimesis mediated by kappa opiate receptors. Science. 1986 ; 233: 774-776
140. Pierri JN, Chaudry AS, Woo TU, et al. Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. Am J Psychiatry. 1999 ; 156: 1709-1719
141. Pilowsky LS, Bressan RA, Stone JM, et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry. 2006 ; 11: 118-119
142. Pinault D. N-methyl d-aspartate receptor antagonists ketamine and MK-801 induce wake-related aberrant gamma oscillations in the rat neocortex. Biol Psychiatry. 2008 ; 63: 730-735
143. Plourde G, Baribeau J, Bonhomme V. Ketamine increases the amplitude of the 40-Hz auditory steady-state response in humans. Br J Anaesth. 1997 ; 78: 524-529
144. Poon CS, Merrill CK. Decrease of cardiac chaos in congestive heart failure. Nature. 1997 ; 389: 492-495
145. Raichle ME, Mintun MA. Brain work and brain imaging. Annu Rev Neurosci. 2006 ; 29: 449-476
146. Rais M, Cahn W, Schnack HG, et al. Brain volume reductions in medication-naive patients with schizophrenia in relation to intelligence quotient. Psychol Med. 2012 ; 42: 1847-1856
147. Rais M, Cahn W, Van Haren N, et al. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am J Psychiatry. 2008 ; 165: 490-496
148. Reich DL, Silvay G. Ketamine: An update on the first twenty-five years of clinical experience. Can J Anaesth. 1989 ; 36: 186-197
149. Rickles D, Hawe P, Shiell A. A simple guide to chaos and complexity. J Epidemiol Community Health. 2007 ; 61: 933-937
150. Roberts BM, Seymour PA, Schmidt CJ, et al. Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists. Psychopharmacology. 2010 ; 210: 407-418
151. Roopun AK, Cunningham MO, Racca C, et al. Region-specific changes in gamma and beta2 rhythms in NMDA receptor dysfunction models of schizophrenia. Schizophr Bull. 2008 ; 34: 962-973
152. Rowland LM. Subanesthetic ketamine: How it alters physiology and behavior in humans. Aviat Space Environ Med. 2005 ; 76: C52 - C58
153. Rowland LM, Bustillo JR, Mullins PG, et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: A 4-T proton MRS study. Am J Psychiatry. 2005 ; 162: 394-396
154. Royston MC, Slater P, Simpson MD, et al. Analysis of laminar distribution of kappa opiate receptor in human cortex: Comparison between schizophrenia and normal. J Neurosci Methods. 1991 ; 36: 145-153
155. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time?. Arch Gen Psychiatry. 2007 ; 64: 1123-1131
156. Sawaguchi T, Goldman-Rakic PS. D1 dopamine receptors in prefrontal cortex: Involvement in working memory. Science. 1991 ; 251: 947-950
157. Scheidegger M, Walter M, Lehmann M, et al. Ketamine decreases resting state functional network connectivity in healthy subjects: Implications for antidepressant drug action. PloS One. 2012 ; 7: e44799
158. Scheller M, Bufler J, Hertle I, et al. Ketamine blocks currents through mammalian nicotinic acetylcholine receptor channels by interaction with both the open and the closed state. Anesth Analg. 1996 ; 83: 830-836
159. Sheffler DJ, Roth BL. Salvinorin A: The 'magic mint' hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci. 2003 ; 24: 107-109
160. Shibuya H, Mori H, Toru M. Sigma receptors in schizophrenic cerebral cortices. Neurochem Res. 1992 ; 17: 983-990
161. Shimazu S, Katsuki H, Takenaka C, et al. Sigma receptor ligands attenuate N-methyl-D-aspartate cytotoxicity in dopaminergic neurons of mesencephalic slice cultures. Eur J Pharmacol. 2000 ; 388: 139-146
162. Shinkai T, De Luca V, Hwang R, et al. Association analyses of the DAOA/G30 and D-amino-acid oxidase genes in schizophrenia: Further evidence for a role in schizophrenia. Neuromolecular. Med. 2007 ; 9: 169-177
163. Singer W, Gray CM. Visual feature integration and the temporal correlation hypothesis. Annu Rev Neurosci. 1995 ; 18: 555-586
164. Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs. 2011 ; 25: 859-885
165. Smith DJ, Bouchal RL, de Sanctis CA, et al. Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro. Neuropharmacology. 1987 ; 26: 1253-1260
166. Smythies J. The adrenochrome hypothesis of schizophrenia revisited. Neurotox Res. 2002 ; 4: 147-150
167. Spencer KM, Nestor PG, Niznikiewicz MA, et al. Abnormal neural synchrony in schizophrenia. J Neurosci. 2003 ; 23: 7407-7411
168. Spencer KM, Nestor PG, Perlmutter R, et al. Neural synchrony indexes disordered perception and cognition in schizophrenia. Proc Natl Acad Sci U S A. 2004 ; 101: 17288-17293
169. Spencer KM, Niznikiewicz MA, Shenton ME, et al. Sensory-evoked gamma oscillations in chronic schizophrenia. Biol Psychiatry. 2008 ; 63: 744-747
170. Spencer KM, Salisbury DF, Shenton ME, et al. Gamma-band auditory steady-state responses are impaired in first episode psychosis. Biol Psychiatry. 2008 ; 64: 369-375
171. Sporns O Networks of the Brain. Cambridge, MA: MIT Press ; 2011 :
172. Sporns O Discovering the Human Connectome. Cambridge, MA: MIT Press ; 2012 :
173. Stam CJ. Nonlinear dynamical analysis of EEG and MEG: Review of an emerging field. Clin Neurophysiol. 2005 ; 116: 2266-2301
174. Stone JM, Dietrich C, Edden R, et al. Ketamine effects on brain GABA and glutamate levels with 1H-MRS: Relationship to ketamine-induced psychopathology. Mol Psychiatry. 2012 ; 17: 664-665
175. Stone JM, Erlandsson K, Arstad E, et al. Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: A [(123)I]CNS-1261 SPET study. Psychopharmacology. 2008 ; 197: 401-408
176. Supplisson S, Bergman C. Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes. J Neurosci. 1997 ; 17: 4580-4590
177. Tagliazucchi E, Balenzuela P, Fraiman D, et al. Criticality in large-scale brain fMRI dynamics unveiled by a novel point process analysis. Front Physiol. 2012 ; 3: 15
178. Talbot K, Eidem WL, Tinsley CL, et al. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest. 2004 ; 113: 1353-1363
179. Tallon-Baudry C, Bertrand O, Peronnet F, et al. Induced gamma-band activity during the delay of a visual short-term memory task in humans. J Neurosci. 1998 ; 18: 4244-4254
180. Tam SW, Cook L. Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes. Proc Natl Acad Sci U S A. 1984 ; 81: 5618-5621
181. Tejeda HA, Shippenberg TS, Henriksson R. The dynorphin/κ-opioid receptor system and its role in psychiatric disorders. Cell Mol Life Sci. 2012 ; 69: 857-896
182. Thornberg SA, Saklad SR. A review of NMDA receptors and the phencyclidine model of schizophrenia. Pharmacotherapy. 1996 ; 16: 82-93
183. Tiitinen H, Sinkkonen J, Reinikainen K, et al. Selective attention enhances the auditory 40-Hz transient response in humans. Nature. 1993 ; 364: 59-60
184. Tononi G, Edelman GM. Schizophrenia and the mechanisms of conscious integration. Brain Res Brain Res Rev. 2000 ; 31: 391-400
185. Traub R D, Whittington M A, Stanford IM, et al. A mechanism for generation of long-range synchronous fast oscillations in the cortex. Nature. 1996 ; 383: 621-624
186. Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol. 2002 ; 42: 165-179
187. Tsai G, Yang P, Chung LC, et al. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 1998 ; 44: 1081-1089
188. Tsai GE, Lin P-Y. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des. 2010 ; 16: 522-537
189. Turing AM. The chemical basis of morphogenesis. Philos Trans R Soc Lond B Biol Sci. 1952 ; 237: 37-72
190. Uhlhaas PJ. Dysconnectivity, large-scale networks and neuronal dynamics in schizophrenia. Curr Opin Neurobiol. 2013 ; 23: 283-290
191. Uhlhaas PJ, Singer W. The development of neural synchrony and large-scale cortical networks during adolescence: Relevance for the pathophysiology of schizophrenia and neurodevelopmental hypothesis. Schizophr Bull. 2011 ; 37: 514-523
192. Uhlhaas PJ, Singer W. Neuronal dynamics and neuropsychiatric disorders: Toward a translational paradigm for dysfunctional large-scale networks. Neuron. 2012 ; 75: 963-980
193. Umbricht D, Koller R, Vollenweider FX, et al. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol Psychiatry. 2002 ; 51: 400-406
194. Voisey J, Swagell CD, Hughes IP, et al. A polymorphism in the dysbindin gene (DTNBP1) associated with multiple psychiatric disorders including schizophrenia. Behav Brain Funct. 2010 ; 6: 41
195. Volk D, Austin M, Pierri J, et al. GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: Decreased expression in a subset of neurons. Am J Psychiatry. 2001 ; 158: 256-265
196. Volk DW, Austin MC, Pierri JN, et al. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry. 2000 ; 57: 237-245
197. Volkow ND, Wolf AP, Brodie JD, et al. Brain interactions in chronic schizophrenics under resting and activation conditions. Schizophr Res. 1988 ; 1: 47-53
198. Vollenweider FX, Leenders KL, Oye I, et al. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol. 1997 ; 7: 25-38
199. Voss LJ, Baas CH, Hansson L, et al. Investigation into the effect of the general anaesthetics etomidate and ketamine on long-range coupling of population activity in the mouse neocortical slice. Eur J Pharmacol. 2012 ; 689: 111-117
200. Wang Q, Deng W, Huang C, et al. Abnormalities in connectivity of white-matter tracts in patients with familial and non-familial schizophrenia. Psychol Med. 2011 ; 41: 1691-1700
201. Weickert CS, Straub RE, McClintock BW, et al. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch Gen Psychiatry. 2004 ; 61: 544-555
202. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987 ; 44: 660-669
203. Weissman AD, Casanova MF, Kleinman JE, et al. Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol Psychiatry. 1991 ; 29: 41-54
204. Wernicke C Grundrisse der Psychiatrie. Leipzig, Germany: Thieme ; 1906 :
205. Whitfield-Gabrieli S, Thermenos HW, Milanovic S, et al. Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proc Natl Acad Sci U S A. 2009 ; 106: 1279-1284
206. Whittemore ER, Ilyin VI, Woodward RM. Antagonism of N-methyl-D-aspartate receptors by sigma site ligands: Potency, subtype-selectivity and mechanisms of inhibition. J Pharmacol Exp Ther. 1997 ; 282: 326-338
207. Williams LM, Whitford TJ, Nagy M, et al. Emotion-elicited gamma synchrony in patients with first-episode schizophrenia: A neural correlate of social cognition outcomes. J Psychiatry Neurosci. 2009 ; 34: 303-313
208. World Health Organization (WHO) (2011) WHO Model Lists of Essential Medicines, 17th list. Available at: http://www.who.int/medicines/publications/ essentialmedicines/en/index.html (accessed 23 June 2013).
209. Wozniak DF, Dikranian K, Ishimaru MJ, et al. Disseminated corticolimbic neuronal degeneration induced in rat brain by MK-801: Potential relevance to Alzheimer's disease. Neurobiol Dis. 1998 ; 5: 305-322
210. Wylie GR, Clark EA, Butler PD, et al. Schizophrenia patients show task switching deficits consistent with N-methyl-d-aspartate system dysfunction but not global executive deficits: Implications for pathophysiology of executive dysfunction in schizophrenia. Schizophr Bull. 2010 ; 36: 585-594
211. Yamakage M, Hirshman CA, Croxton TL. Inhibitory effects of thiopental, ketamine, and propofol on voltage-dependent Ca2+ channels in porcine tracheal smooth muscle cells. Anesthesiology. 1995 ; 83: 1274-1282
212. Yonezawa Y, Kuroki T, Kawahara T, et al. Involvement of gamma-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex. Eur J Pharmacol. 1998 ; 341: 45-56
213. Zalesky A, Fornito A, Seal ML, et al. Disrupted axonal fiber connectivity in schizophrenia. Biol Psychiatry. 2011 ; 69: 80-89
214. Zhou L, Welsh AM, Chen D, et al. NMDA inhibitors cause apoptosis of pyramidal neurons in mature piriform cortex: Evidence for a nitric oxide-mediated effect involving inhibitory interneurons. Neuropharmacology. 2007 ; 52: 1528-1537